Global Injectable Drug Delivery Formulation research

Injectable Drug Delivery Formulation Comprehensive Study by Type (Conventional Drug Delivery Formulations, Novel Drug Delivery Formulations, Long-acting Formulations), Application (Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Others) Players and Region - Global Market Outlook to 2030

Injectable Drug Delivery Formulation Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 7.2%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Injectable Drug Delivery Formulation
Injectable drug delivery is considered one of the most effective routes of administration due to the speed and effectiveness of delivery to the target, as well as the improved patient experience. Injectable drug delivery formulation is a dosage form that is commonly used in pharmaceuticals to treat various diseases.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR7.2%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Injectable Drug Delivery Formulation market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Becton, Dickinson and Company (United States), Baxter International Inc. (United States), Gerresheimer AG (Germany), Pfizer, Inc. (United States), Schott AG (Germany), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel) and Eli Lilly and Company (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Injectable Drug Delivery Formulation market by Type (Conventional Drug Delivery Formulations, Novel Drug Delivery Formulations and Long-acting Formulations), Application (Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases and Others) and Region.



On the basis of geography, the market of Injectable Drug Delivery Formulation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Technological Advancements and New Product Launches

Market Growth Drivers:
The Rising Prevalence of Chronic Disease and The Rising Geriatric Population Globally

Challenges:
High competition

Restraints:
Product Recalls

Opportunities:
The Growth Opportunities from Developing Countries

Market Leaders and their expansionary development strategies
In December 2023, Viridian Therapeutics, Inc. recently announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse innovative wearable drug delivery system for volumes of up to 25 mL. As we expand our pipeline beyond TED and assess the unmet needs of patients living with other serious and rare diseases, it’s clear that convenient drug delivery is an important issue.
In November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States. Market availability of the product in the U.S. is expected in the coming weeks.


Key Target Audience
Injectable Drug Delivery Formulation Manufacturers, Injectable Drug Delivery Formulation Traders/Distributors, Injectable Drug Delivery Formulation Importer/Exporter, Regulatory & Government Bodies, End Users and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Conventional Drug Delivery Formulations
  • Novel Drug Delivery Formulations
  • Long-acting Formulations
By Application
  • Autoimmune Diseases
  • Hormonal Disorders
  • Oncology
  • Orphan Diseases
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Prevalence of Chronic Disease
      • 3.2.2. The Rising Geriatric Population Globally
    • 3.3. Market Challenges
      • 3.3.1. High competition
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements and New Product Launches
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Injectable Drug Delivery Formulation, by Type, Application and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Injectable Drug Delivery Formulation (Value)
      • 5.2.1. Global Injectable Drug Delivery Formulation by: Type (Value)
        • 5.2.1.1. Conventional Drug Delivery Formulations
        • 5.2.1.2. Novel Drug Delivery Formulations
        • 5.2.1.3. Long-acting Formulations
      • 5.2.2. Global Injectable Drug Delivery Formulation by: Application (Value)
        • 5.2.2.1. Autoimmune Diseases
        • 5.2.2.2. Hormonal Disorders
        • 5.2.2.3. Oncology
        • 5.2.2.4. Orphan Diseases
        • 5.2.2.5. Others
      • 5.2.3. Global Injectable Drug Delivery Formulation Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Injectable Drug Delivery Formulation (Volume)
      • 5.3.1. Global Injectable Drug Delivery Formulation by: Type (Volume)
        • 5.3.1.1. Conventional Drug Delivery Formulations
        • 5.3.1.2. Novel Drug Delivery Formulations
        • 5.3.1.3. Long-acting Formulations
      • 5.3.2. Global Injectable Drug Delivery Formulation by: Application (Volume)
        • 5.3.2.1. Autoimmune Diseases
        • 5.3.2.2. Hormonal Disorders
        • 5.3.2.3. Oncology
        • 5.3.2.4. Orphan Diseases
        • 5.3.2.5. Others
      • 5.3.3. Global Injectable Drug Delivery Formulation Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Injectable Drug Delivery Formulation (Price)
      • 5.4.1. Global Injectable Drug Delivery Formulation by: Type (Price)
  • 6. Injectable Drug Delivery Formulation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Becton, Dickinson and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Baxter International Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Gerresheimer AG (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Schott AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sandoz (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Injectable Drug Delivery Formulation Sale, by Type, Application and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Injectable Drug Delivery Formulation (Value)
      • 7.2.1. Global Injectable Drug Delivery Formulation by: Type (Value)
        • 7.2.1.1. Conventional Drug Delivery Formulations
        • 7.2.1.2. Novel Drug Delivery Formulations
        • 7.2.1.3. Long-acting Formulations
      • 7.2.2. Global Injectable Drug Delivery Formulation by: Application (Value)
        • 7.2.2.1. Autoimmune Diseases
        • 7.2.2.2. Hormonal Disorders
        • 7.2.2.3. Oncology
        • 7.2.2.4. Orphan Diseases
        • 7.2.2.5. Others
      • 7.2.3. Global Injectable Drug Delivery Formulation Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Injectable Drug Delivery Formulation (Volume)
      • 7.3.1. Global Injectable Drug Delivery Formulation by: Type (Volume)
        • 7.3.1.1. Conventional Drug Delivery Formulations
        • 7.3.1.2. Novel Drug Delivery Formulations
        • 7.3.1.3. Long-acting Formulations
      • 7.3.2. Global Injectable Drug Delivery Formulation by: Application (Volume)
        • 7.3.2.1. Autoimmune Diseases
        • 7.3.2.2. Hormonal Disorders
        • 7.3.2.3. Oncology
        • 7.3.2.4. Orphan Diseases
        • 7.3.2.5. Others
      • 7.3.3. Global Injectable Drug Delivery Formulation Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Injectable Drug Delivery Formulation (Price)
      • 7.4.1. Global Injectable Drug Delivery Formulation by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Injectable Drug Delivery Formulation: by Type(USD Million)
  • Table 2. Injectable Drug Delivery Formulation Conventional Drug Delivery Formulations , by Region USD Million (2018-2023)
  • Table 3. Injectable Drug Delivery Formulation Novel Drug Delivery Formulations , by Region USD Million (2018-2023)
  • Table 4. Injectable Drug Delivery Formulation Long-acting Formulations , by Region USD Million (2018-2023)
  • Table 5. Injectable Drug Delivery Formulation: by Application(USD Million)
  • Table 6. Injectable Drug Delivery Formulation Autoimmune Diseases , by Region USD Million (2018-2023)
  • Table 7. Injectable Drug Delivery Formulation Hormonal Disorders , by Region USD Million (2018-2023)
  • Table 8. Injectable Drug Delivery Formulation Oncology , by Region USD Million (2018-2023)
  • Table 9. Injectable Drug Delivery Formulation Orphan Diseases , by Region USD Million (2018-2023)
  • Table 10. Injectable Drug Delivery Formulation Others , by Region USD Million (2018-2023)
  • Table 11. South America Injectable Drug Delivery Formulation, by Country USD Million (2018-2023)
  • Table 12. South America Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 13. South America Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 14. Brazil Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 15. Brazil Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 16. Argentina Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 17. Argentina Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 18. Rest of South America Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 19. Rest of South America Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 20. Asia Pacific Injectable Drug Delivery Formulation, by Country USD Million (2018-2023)
  • Table 21. Asia Pacific Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 22. Asia Pacific Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 23. China Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 24. China Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 25. Japan Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 26. Japan Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 27. India Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 28. India Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 29. South Korea Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 30. South Korea Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 31. Taiwan Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 32. Taiwan Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 33. Australia Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 34. Australia Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 35. Rest of Asia-Pacific Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 37. Europe Injectable Drug Delivery Formulation, by Country USD Million (2018-2023)
  • Table 38. Europe Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 39. Europe Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 40. Germany Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 41. Germany Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 42. France Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 43. France Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 44. Italy Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 45. Italy Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 46. United Kingdom Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 47. United Kingdom Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 48. Netherlands Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 49. Netherlands Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 50. Rest of Europe Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 51. Rest of Europe Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 52. MEA Injectable Drug Delivery Formulation, by Country USD Million (2018-2023)
  • Table 53. MEA Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 54. MEA Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 55. Middle East Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 56. Middle East Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 57. Africa Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 58. Africa Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 59. North America Injectable Drug Delivery Formulation, by Country USD Million (2018-2023)
  • Table 60. North America Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 61. North America Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 62. United States Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 63. United States Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 64. Canada Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 65. Canada Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 66. Mexico Injectable Drug Delivery Formulation, by Type USD Million (2018-2023)
  • Table 67. Mexico Injectable Drug Delivery Formulation, by Application USD Million (2018-2023)
  • Table 68. Injectable Drug Delivery Formulation Sales: by Type(K Tons)
  • Table 69. Injectable Drug Delivery Formulation Sales Conventional Drug Delivery Formulations , by Region K Tons (2018-2023)
  • Table 70. Injectable Drug Delivery Formulation Sales Novel Drug Delivery Formulations , by Region K Tons (2018-2023)
  • Table 71. Injectable Drug Delivery Formulation Sales Long-acting Formulations , by Region K Tons (2018-2023)
  • Table 72. Injectable Drug Delivery Formulation Sales: by Application(K Tons)
  • Table 73. Injectable Drug Delivery Formulation Sales Autoimmune Diseases , by Region K Tons (2018-2023)
  • Table 74. Injectable Drug Delivery Formulation Sales Hormonal Disorders , by Region K Tons (2018-2023)
  • Table 75. Injectable Drug Delivery Formulation Sales Oncology , by Region K Tons (2018-2023)
  • Table 76. Injectable Drug Delivery Formulation Sales Orphan Diseases , by Region K Tons (2018-2023)
  • Table 77. Injectable Drug Delivery Formulation Sales Others , by Region K Tons (2018-2023)
  • Table 78. South America Injectable Drug Delivery Formulation Sales, by Country K Tons (2018-2023)
  • Table 79. South America Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 80. South America Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 81. Brazil Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 82. Brazil Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 83. Argentina Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 84. Argentina Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 85. Rest of South America Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 86. Rest of South America Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 87. Asia Pacific Injectable Drug Delivery Formulation Sales, by Country K Tons (2018-2023)
  • Table 88. Asia Pacific Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 89. Asia Pacific Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 90. China Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 91. China Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 92. Japan Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 93. Japan Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 94. India Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 95. India Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 96. South Korea Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 97. South Korea Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 98. Taiwan Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 99. Taiwan Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 100. Australia Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 101. Australia Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 102. Rest of Asia-Pacific Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 103. Rest of Asia-Pacific Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 104. Europe Injectable Drug Delivery Formulation Sales, by Country K Tons (2018-2023)
  • Table 105. Europe Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 106. Europe Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 107. Germany Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 108. Germany Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 109. France Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 110. France Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 111. Italy Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 112. Italy Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 113. United Kingdom Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 114. United Kingdom Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 115. Netherlands Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 116. Netherlands Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 117. Rest of Europe Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 118. Rest of Europe Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 119. MEA Injectable Drug Delivery Formulation Sales, by Country K Tons (2018-2023)
  • Table 120. MEA Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 121. MEA Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 122. Middle East Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 123. Middle East Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 124. Africa Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 125. Africa Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 126. North America Injectable Drug Delivery Formulation Sales, by Country K Tons (2018-2023)
  • Table 127. North America Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 128. North America Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 129. United States Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 130. United States Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 131. Canada Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 132. Canada Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 133. Mexico Injectable Drug Delivery Formulation Sales, by Type K Tons (2018-2023)
  • Table 134. Mexico Injectable Drug Delivery Formulation Sales, by Application K Tons (2018-2023)
  • Table 135. Injectable Drug Delivery Formulation: by Type(USD/Units)
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Injectable Drug Delivery Formulation: by Type(USD Million)
  • Table 145. Injectable Drug Delivery Formulation Conventional Drug Delivery Formulations , by Region USD Million (2025-2030)
  • Table 146. Injectable Drug Delivery Formulation Novel Drug Delivery Formulations , by Region USD Million (2025-2030)
  • Table 147. Injectable Drug Delivery Formulation Long-acting Formulations , by Region USD Million (2025-2030)
  • Table 148. Injectable Drug Delivery Formulation: by Application(USD Million)
  • Table 149. Injectable Drug Delivery Formulation Autoimmune Diseases , by Region USD Million (2025-2030)
  • Table 150. Injectable Drug Delivery Formulation Hormonal Disorders , by Region USD Million (2025-2030)
  • Table 151. Injectable Drug Delivery Formulation Oncology , by Region USD Million (2025-2030)
  • Table 152. Injectable Drug Delivery Formulation Orphan Diseases , by Region USD Million (2025-2030)
  • Table 153. Injectable Drug Delivery Formulation Others , by Region USD Million (2025-2030)
  • Table 154. South America Injectable Drug Delivery Formulation, by Country USD Million (2025-2030)
  • Table 155. South America Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 156. South America Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 157. Brazil Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 158. Brazil Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 159. Argentina Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 160. Argentina Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 161. Rest of South America Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 162. Rest of South America Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 163. Asia Pacific Injectable Drug Delivery Formulation, by Country USD Million (2025-2030)
  • Table 164. Asia Pacific Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 165. Asia Pacific Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 166. China Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 167. China Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 168. Japan Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 169. Japan Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 170. India Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 171. India Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 172. South Korea Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 173. South Korea Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 174. Taiwan Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 175. Taiwan Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 176. Australia Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 177. Australia Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 178. Rest of Asia-Pacific Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 179. Rest of Asia-Pacific Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 180. Europe Injectable Drug Delivery Formulation, by Country USD Million (2025-2030)
  • Table 181. Europe Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 182. Europe Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 183. Germany Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 184. Germany Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 185. France Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 186. France Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 187. Italy Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 188. Italy Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 189. United Kingdom Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 190. United Kingdom Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 191. Netherlands Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 192. Netherlands Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 193. Rest of Europe Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 194. Rest of Europe Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 195. MEA Injectable Drug Delivery Formulation, by Country USD Million (2025-2030)
  • Table 196. MEA Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 197. MEA Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 198. Middle East Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 199. Middle East Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 200. Africa Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 201. Africa Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 202. North America Injectable Drug Delivery Formulation, by Country USD Million (2025-2030)
  • Table 203. North America Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 204. North America Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 205. United States Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 206. United States Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 207. Canada Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 208. Canada Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 209. Mexico Injectable Drug Delivery Formulation, by Type USD Million (2025-2030)
  • Table 210. Mexico Injectable Drug Delivery Formulation, by Application USD Million (2025-2030)
  • Table 211. Injectable Drug Delivery Formulation Sales: by Type(K Tons)
  • Table 212. Injectable Drug Delivery Formulation Sales Conventional Drug Delivery Formulations , by Region K Tons (2025-2030)
  • Table 213. Injectable Drug Delivery Formulation Sales Novel Drug Delivery Formulations , by Region K Tons (2025-2030)
  • Table 214. Injectable Drug Delivery Formulation Sales Long-acting Formulations , by Region K Tons (2025-2030)
  • Table 215. Injectable Drug Delivery Formulation Sales: by Application(K Tons)
  • Table 216. Injectable Drug Delivery Formulation Sales Autoimmune Diseases , by Region K Tons (2025-2030)
  • Table 217. Injectable Drug Delivery Formulation Sales Hormonal Disorders , by Region K Tons (2025-2030)
  • Table 218. Injectable Drug Delivery Formulation Sales Oncology , by Region K Tons (2025-2030)
  • Table 219. Injectable Drug Delivery Formulation Sales Orphan Diseases , by Region K Tons (2025-2030)
  • Table 220. Injectable Drug Delivery Formulation Sales Others , by Region K Tons (2025-2030)
  • Table 221. South America Injectable Drug Delivery Formulation Sales, by Country K Tons (2025-2030)
  • Table 222. South America Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 223. South America Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 224. Brazil Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 225. Brazil Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 226. Argentina Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 227. Argentina Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 228. Rest of South America Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 229. Rest of South America Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 230. Asia Pacific Injectable Drug Delivery Formulation Sales, by Country K Tons (2025-2030)
  • Table 231. Asia Pacific Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 232. Asia Pacific Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 233. China Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 234. China Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 235. Japan Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 236. Japan Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 237. India Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 238. India Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 239. South Korea Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 240. South Korea Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 241. Taiwan Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 242. Taiwan Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 243. Australia Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 244. Australia Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 245. Rest of Asia-Pacific Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 246. Rest of Asia-Pacific Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 247. Europe Injectable Drug Delivery Formulation Sales, by Country K Tons (2025-2030)
  • Table 248. Europe Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 249. Europe Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 250. Germany Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 251. Germany Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 252. France Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 253. France Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 254. Italy Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 255. Italy Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 256. United Kingdom Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 257. United Kingdom Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 258. Netherlands Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 259. Netherlands Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 260. Rest of Europe Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 261. Rest of Europe Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 262. MEA Injectable Drug Delivery Formulation Sales, by Country K Tons (2025-2030)
  • Table 263. MEA Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 264. MEA Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 265. Middle East Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 266. Middle East Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 267. Africa Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 268. Africa Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 269. North America Injectable Drug Delivery Formulation Sales, by Country K Tons (2025-2030)
  • Table 270. North America Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 271. North America Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 272. United States Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 273. United States Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 274. Canada Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 275. Canada Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 276. Mexico Injectable Drug Delivery Formulation Sales, by Type K Tons (2025-2030)
  • Table 277. Mexico Injectable Drug Delivery Formulation Sales, by Application K Tons (2025-2030)
  • Table 278. Injectable Drug Delivery Formulation: by Type(USD/Units)
  • Table 279. Research Programs/Design for This Report
  • Table 280. Key Data Information from Secondary Sources
  • Table 281. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Injectable Drug Delivery Formulation: by Type USD Million (2018-2023)
  • Figure 5. Global Injectable Drug Delivery Formulation: by Application USD Million (2018-2023)
  • Figure 6. South America Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 7. Asia Pacific Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 8. Europe Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 9. MEA Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 10. North America Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 11. Global Injectable Drug Delivery Formulation: by Type K Tons (2018-2023)
  • Figure 12. Global Injectable Drug Delivery Formulation: by Application K Tons (2018-2023)
  • Figure 13. South America Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 14. Asia Pacific Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 15. Europe Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 16. MEA Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 17. North America Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 18. Global Injectable Drug Delivery Formulation: by Type USD/Units (2018-2023)
  • Figure 19. Global Injectable Drug Delivery Formulation share by Players 2023 (%)
  • Figure 20. Global Injectable Drug Delivery Formulation share by Players (Top 3) 2023(%)
  • Figure 21. Global Injectable Drug Delivery Formulation share by Players (Top 5) 2023(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 24. Becton, Dickinson and Company (United States) Revenue: by Geography 2023
  • Figure 25. Baxter International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Baxter International Inc. (United States) Revenue: by Geography 2023
  • Figure 27. Gerresheimer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Gerresheimer AG (Germany) Revenue: by Geography 2023
  • Figure 29. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 31. Schott AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Schott AG (Germany) Revenue: by Geography 2023
  • Figure 33. Sandoz (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Sandoz (Germany) Revenue: by Geography 2023
  • Figure 35. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 36. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 37. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 38. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 39. Global Injectable Drug Delivery Formulation: by Type USD Million (2025-2030)
  • Figure 40. Global Injectable Drug Delivery Formulation: by Application USD Million (2025-2030)
  • Figure 41. South America Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 42. Asia Pacific Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 43. Europe Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 44. MEA Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 45. North America Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 46. Global Injectable Drug Delivery Formulation: by Type K Tons (2025-2030)
  • Figure 47. Global Injectable Drug Delivery Formulation: by Application K Tons (2025-2030)
  • Figure 48. South America Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 49. Asia Pacific Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 50. Europe Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 51. MEA Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 52. North America Injectable Drug Delivery Formulation Share (%), by Country
  • Figure 53. Global Injectable Drug Delivery Formulation: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Becton, Dickinson and Company (United States)
  • Baxter International Inc. (United States)
  • Gerresheimer AG (Germany)
  • Pfizer, Inc. (United States)
  • Schott AG (Germany)
  • Sandoz (Germany)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Eli Lilly and Company (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 206 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Injectable Drug Delivery Formulation research Quantitative research analysis
Global Injectable Drug Delivery Formulation research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Becton, Dickinson and Company (United States), Baxter International Inc. (United States), Gerresheimer AG (Germany), Pfizer, Inc. (United States), Schott AG (Germany), Sandoz (Germany), Teva Pharmaceutical Industries Ltd. (Israel) and Eli Lilly and Company (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements and New Product Launches" is seen as one of major influencing trends for Injectable Drug Delivery Formulation Market during projected period 2023-2030.
The Injectable Drug Delivery Formulation market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Injectable Drug Delivery Formulation research Report?

Have a Query? Click Here

Other Related Reports

Competent Cells Comprehensive Study by Type (Cloned Competent Cells, Agrobacterium Tumefaciens Competent Cells, Expression Competent Cells), Application (Cloning {Subcloning & Routine Cloning, Phage ...
$ 3750
Oral Vaccines Comprehensive Study by Type (Live (attenuated), Inactive, Recombinant, Other), Application (Polio, Rabies, Tuberculosis, Influenza, Respiratory infections, HIV, Cholera, Rotavirus, Othe...
$ 3450
Biobanking Comprehensive Study by Type (Equipment, Consumables, Services, Software), Application (Regenerative Medicine, Life Science Research, Clinical Research), Ownership (National/Regional Agenci...
$ 3750
Clinical Microbiology Comprehensive Study by Application (Pharmaceutical, Food Testing, Energy, Chemical and Material Manufacturing, Environment), End Users (Hospital, Diagnolab, Academia), Disease (...
$ 3750
Animal Hormones Comprehensive Study by Application (Growth Promoters, Performance Enhancers, Others), End-Use (Poultry, Porcine, Livestock, Equine, Aquaculture, Other) Players and Region - Global Mar...
$ 3500
Exosomes Comprehensive Study by Application (Cancer, Neurodegenerative diseases, Cardiovascular diseases, Infectious diseases, Others), Downstream Analysis (Cell Surface Marker Analysis using Flow Cy...
$ 3750